HIGH miR-142-3p EXPRESSION IN PERIPHERAL BLOOD OF PATIENTS WITH OVARIAN CARCINOMA

Abstract

Objectives: The fact that ovarian cancer manifests itself in the late stage and is characterized by a poor prognosis, is caused death in the majority of cases. miRNAs being as the biomarker candidates in diagnosis, and their use in treatment as the inhibitors of the molecules mimicking the miRNA showed that they may be used as the new therapeutic target and agents. Present study aims to determine the effect of expresion level of miR-142-3p in ovarian cancer patients. Material-Methods: We detected with our group in our prior study conducted with disconcordant ovarian cancer twins that many miRNA molecules were different in ovarian cancer compared with the molecules in healthy sibling. The expression level of miR-142-3p that was selected from the miRNAs detected in the previous study was compared, and investigated in a wider ovarian cancer group, and in healthy control group. miR-142-3p expression level was investigated using the real-time PCR method in the present study involving 147 patients, and 100 healthy control group. The differences in the expression levels of miR-142-3p detected in the peripheral blood lymphocytes of ovarian cancer patients, and healthy control were statisticaly evaluated. Results: The expression level of miR-142-3p was detected to have increased 3.11 fold in ovarian cancer patients compared with the levels in healthy controls, and the difference was statistically significant (p:0.00). We suggest that this microRNA showing high expression promoted the oncogenesis of ovarian cells by behaving such an oncogene. miR-142-3p expression level, and the clinical data,diagnosis, and family histories were analysed in details. Conclusions: These results suggest that miR-142-3p that was found significantly increased in the peripheral blood samples of ovarian cancer patients compared with the healthy controls might be used as a sensitive, noninvasive biomarker in the early diagnosis, and treatment and follow up of ovarian cancer.